Product Information
Registration Status: ActiveISOFLURANE INHALATION is approved to be sold in Singapore with effective from 1994-11-15. It is marketed by EMERGING PHARMA (S) PTE LTD, with the registration number of SIN07914P.
This product contains Isoflurane 100% in the form of SOLUTION. It is approved for NASAL use.
This product is manufactured by Piramal Healthcare LTD in INDIA.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Description
A stable, non-explosive inhalation anesthetic, relatively free from significant side effects.
Indication
For induction and maintenance of general anesthesia.
Mechanism of Action
Isoflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Isoflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. Also appears to bind the D subunit of ATP synthase and NADH dehydogenase. Isoflurane also binds to the GABA receptor, the large conductance Ca2+ activated potassium channel, the glutamate receptor and the glycine receptor.
Toxicity
LC50=15300 ppm/3 hrs (inhalation by rat)
Active Ingredient/Synonyms
1-chloro-2,2,2-trifluoroethyl difluoromethyl ether | Isoflurane | Isoflurano | Isofluranum | Isoflurane |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.